Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply. Johnston SRD, Andre V. Lancet Oncol 2023;24:e104.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Johnston SRD, Andre V. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply. Lancet Oncol 2023;24:e104.
PMID: 36858725